recent
identifi
cycloguanillik
dihydrotriazin
deriv
provid
hostfactor
direct
antivir
activ
influenza
virus
respiratori
syncyti
viru
rsv
target
human
dihydrofol
reductas
hdhfr
enzym
context
deem
interest
investig
structur
activ
relationship
sar
first
seri
cycloguanillik
dihydrotriazin
design
two
novel
azaspiro
dihydrotriazin
scaffold
present
studi
allow
explor
potenti
chemic
space
around
new
scaffold
well
toler
maintain
antivir
effect
mean
interact
hdhfr
enzym
new
deriv
confirm
inhibitori
profil
influenza
virus
especi
type
b
particular
two
best
compound
share
potent
antivir
activ
ec
mm
ec
mm
compar
zanamivir
ec
mm
better
ribavirin
ec
mm
addit
two
compound
prove
also
effect
rsv
ec
mm
si
ec
mm
si
surpass
potenc
select
index
si
ribavirin
ec
mm
si
perspect
result
adequ
substitut
azaspiro
dihydrotriazin
may
repres
valuabl
hit
compound
worthi
structur
optim
develop
improv
host
dhfrdirect
antivir
agent
besid
vaccin
therapeut
strategi
combat
infecti
diseas
mainli
target
uniqu
enzym
compon
virus
bacteria
parasit
approv
pathogendirect
approach
highli
success
mani
case
face
rise
resist
individu
drug
drug
class
also
occur
field
influenza
viru
influenza
epidem
pandem
continu
global
threat
human
health
influenza
therapi
current
restrict
two
class
virusdirect
drug
ion
channel
blocker
neuraminidas
inhibitor
first
class
suffer
global
viru
resist
neurolog
side
effect
altern
neuraminidas
inhibitor
also
induc
resist
provid
rather
modest
clinic
outcom
highlight
urgent
need
develop
new
antivir
strategi
entir
novel
action
principl
reduc
risk
drug
resist
altern
concept
design
new
molecul
target
host
cell
factor
hijack
viru
replic
host
factordirect
antivir
therapi
increasingli
recogn
relev
approach
counteract
viral
resist
provid
broadspectrum
antivir
agent
studi
virushost
interact
allow
identif
mechan
viral
factor
coopt
host
cell
function
host
regulatori
mechan
influenc
diseas
progress
treatment
outcom
host
factor
may
potenti
drug
target
diseas
manag
host
factor
influenza
viru
rsv
dengu
viru
human
immunodefici
viru
hiv
recogn
transcriptom
proteom
method
provid
detail
biochem
insight
replic
strategi
virus
gener
hostdirect
antiinfect
intervent
may
enhanc
host
cell
respons
pathogen
target
diseasecaus
virul
factor
stimul
innat
adapt
immun
respons
today
differ
class
antiinfluenza
agent
develop
target
viral
cellular
protein
process
context
initi
program
develop
new
antivir
chemotyp
toward
host
factor
implic
viru
replic
host
human
dihydrofol
reductas
dhfr
recent
identifi
enzym
molecular
target
structur
relat
antimalari
drug
cycloguanil
fig
class
host
dhfr
inhibitor
possess
intrigu
dual
activ
influenza
b
virus
rsv
promis
deriv
rang
ec
mm
potenc
influenza
b
compar
zanamivir
antivir
ec
mm
neuraminidas
inhibitor
global
advis
influenza
therapi
dhfr
inhibitor
also
exhibit
nanomolar
activ
mean
ec
mm
rsv
si
ratio
cytotox
antivir
concentr
compound
far
surpass
potenc
safeti
profil
antirsv
drug
ribavirin
ec
mm
si
report
detail
investig
probe
antivir
activ
two
novel
scaffold
compound
see
fig
orthomyxoviru
influenza
b
paramyxoviru
rsv
repres
new
dihydrotriazin
design
order
better
explor
chemic
space
around
scaffold
well
toler
target
host
human
dhfr
enzym
view
evalu
effect
viru
inhibit
new
compound
confirm
inhibitori
profil
influenza
virus
especi
type
b
order
verifi
hostfactor
dhfr
molecular
target
also
azaspiro
dihydrotriazin
promis
deriv
assay
recombin
hdhfr
investig
accompani
molecular
model
studi
titl
compound
complex
hdhfr
predict
import
featur
underli
proteinligand
bind
inform
suggest
key
molecular
interact
requir
achiev
pharmacolog
activ
help
ration
observ
sar
dihydrotriazinecontain
deriv
act
host
human
dhfr
inhibitor
explor
azaspiro
dihydrotriazin
core
toward
host
dhfrdirect
antivir
molecul
previou
seri
cycloguanillik
dihydrotriazin
deriv
n
dihydrotriazin
directli
link
phenyl
ring
various
substitut
electronwithdraw
electrondon
group
whilst
two
methyl
group
c
correspond
new
spiran
c
see
experiment
section
cycloguanil
sometim
replac
smaller
bulkier
alkyl
group
investig
sar
class
compound
fig
two
novel
scaffold
fig
explor
obtain
exploit
synthet
step
versatil
build
block
allow
via
nitrogen
atom
introduct
addit
reactiv
center
molecular
diversif
new
twentythre
deriv
function
n
posit
dihydrotriazin
core
aromat
ring
fig
fig
aliphat
chain
propyl
methoxyethyl
fig
dihydrotriazin
spiran
c
includ
piperidin
nucleu
whose
nitrogen
atom
para
posit
decor
larg
differ
substitut
chain
reaction
acyl
chlorid
sulfonyl
chlorid
isocyan
carboxyl
acid
deliv
amid
ureido
function
nitrogen
atom
azaspiro
moieti
meta
posit
benzyl
substitu
explor
previou
seri
cycloguanillik
dihydrotriazin
deriv
bulki
cycloalkyl
group
c
posit
dihydrotriazin
ring
well
toler
term
inhibitori
activ
toward
hdhfr
yield
less
effect
antivir
compound
novel
deriv
piperidin
nucleu
creat
opportun
form
new
addit
interact
enabl
us
probe
steric
electron
toler
side
chain
hdhfr
activ
site
compound
prepar
threestep
synthet
rout
first
step
proper
amin
cyanoguanidin
react
acid
catalyz
condit
scheme
protect
group
remov
trifluoroacet
acid
scheme
last
step
piperidin
nitrogen
react
acyl
chlorid
sulfonyl
chlorid
isocyan
carboxyl
acid
obtain
correspond
amid
ureido
function
scheme
one
pot
reaction
proper
anilin
deriv
previous
convert
hydrochlorid
salt
dicyandiamid
reflux
h
provid
compound
scheme
compound
crystal
directli
reaction
mixtur
pure
hydrochlorid
new
compound
show
analyt
spectroscop
data
agreement
structur
see
experiment
part
puriti
compound
check
hplc
element
analys
result
case
first
seri
cycloguanillik
dihydrotriazin
deriv
ie
compound
fig
convent
nomenclatur
dihydrotriazin
ring
attribut
posit
substitut
n
atom
posit
dimethyl
substitut
c
atom
new
compound
seri
presenc
spiropiperidin
ring
impos
differ
number
substitu
dihydrotriazin
nucleu
posit
unchang
disubstitut
c
becom
new
spiran
c
parallel
cytotox
compound
determin
microscopi
mt
assay
yield
mcc
cc
valu
respect
tabl
addit
target
compound
test
divers
panel
virus
includ
rsv
tabl
highli
suscept
previous
report
seri
cycloguanillik
dihydrotriazin
depict
fig
although
test
compound
direct
toward
host
cell
enzym
produc
margin
cytotox
mm
human
cervix
carcinoma
hela
african
green
monkey
vero
result
shown
cell
cultur
highli
prolifer
due
addit
fetal
calf
serum
fc
infect
medium
somewhat
higher
cytotox
observ
mdck
cell
activ
divid
influenza
assay
due
use
ultramdck
medium
special
medium
enabl
work
fcsfree
condit
ad
trypsin
achiev
multicycl
influenza
replic
instanc
two
potent
antivir
compound
mcc
mm
mm
yet
cytotox
concentr
valu
ie
cc
assess
mt
cell
viabil
assay
mm
respect
higher
correspond
mcc
valu
antivir
activ
eight
synthes
compound
activ
influenza
b
viru
ec
valu
rang
mm
four
eight
influenza
b
hit
activ
influenza
two
also
activ
rsv
ec
mm
respect
compound
exhibit
similar
activ
influenza
b
rsv
ec
valu
mm
respect
pvalu
twosid
student
ttest
antiinfluenza
potenc
compar
zanamivir
ec
mm
higher
ribavirin
influenza
b
exhibit
favor
si
ratio
cc
ec
even
higher
activ
particular
select
note
compound
ec
mm
si
similarli
also
activ
rsv
result
indic
dhfr
enzym
equal
import
support
influenza
replic
mdck
cell
allow
rsv
replic
hela
cell
mdck
hela
prototyp
cell
line
antivir
research
influenza
rsv
respect
sinc
give
robust
viru
replic
cpe
previou
set
cycloguanillik
deriv
bore
n
dihydrotriazin
core
various
substitut
aromat
ring
lipophil
electronwithdraw
group
posit
properli
condit
antivir
activ
demonstr
submicromolar
rang
potenc
ec
mm
influenza
b
viru
analyz
role
substitu
n
posit
new
dihydrotriazin
phenyl
ring
provid
activ
influenza
b
case
influenza
viru
wherea
moieti
npropyl
methoxyethyl
chain
abolish
activ
except
deriv
display
ec
mm
influenza
b
viru
molecul
combin
methoxyethyl
substitut
n
ethylsulfon
group
decor
spiropiperidin
nitrogen
base
posit
result
previou
seri
cycloguanil
analog
substitu
includ
phenyl
ring
n
posit
dihydrotriazin
fig
data
confirm
atom
enhanc
antivir
potenc
influenza
b
wherea
group
less
effect
place
two
methyl
group
potent
cycloguanillik
deriv
new
dihydrotriazin
bore
spiropiperidin
ring
whose
nitrogen
atom
differ
function
regard
influenc
r
variat
piperidin
nitrogen
carbam
amid
ureido
function
permit
lack
substitu
abolish
activ
among
activ
compound
bear
amid
function
ring
provid
highest
potenc
influenza
b
ec
mm
better
analog
carri
naphthyl
cyclobutyl
moieti
respect
worth
note
antivir
activ
mainli
determin
presenc
phenyl
ring
n
rather
substitu
piperidin
nitrogen
four
substitut
dihydrotriazin
ie
favor
activ
influenza
b
confirm
influenza
viru
remark
two
best
compound
influenza
b
found
inact
influenza
viru
deriv
compar
favor
potenc
safeti
profil
ec
mm
si
respect
substitut
cycloguanil
analog
show
ec
valu
influenza
b
viru
equal
mm
si
respect
howev
cycloguanillik
deriv
remain
unsurpass
provid
better
antivir
activ
select
index
ec
mm
si
respect
hand
two
compound
entir
seri
activ
rsv
superior
si
ratio
mcc
ec
note
respect
term
antirsv
potenc
two
molecul
superior
licens
drug
ribavirin
ec
mm
nonspecif
antirsv
drug
whose
administr
burden
toxic
nevertheless
result
significantli
less
effect
antirsv
agent
cycloguanillik
dihydrotriazin
exhibit
ec
valu
rang
mm
markedli
superior
si
valu
none
compound
investig
display
activ
dna
virus
ie
herp
simplex
viru
adenoviru
vaccinia
viru
envelop
rna
virus
ie
hiv
coronaviru
viru
vesicular
stomat
viru
sindbi
viru
yellow
fever
viru
punta
toro
viru
nonenvelop
rna
virus
ie
coxsackieviru
data
shown
recent
studi
literatur
identifi
new
class
antivir
agent
abl
target
divers
host
factor
indispens
effici
viru
replic
exampl
human
deadbox
polypeptid
inhibitor
phenyl
elicit
interest
broad
spectrum
antivir
activ
hiv
hepat
c
viru
hcv
also
imidazopyridazinyl
benzenesulfonamid
deriv
display
signific
antivir
profil
mean
ec
nm
three
singl
strand
virus
human
rhinoviru
coxsacki
viru
hcv
bgenotyp
impair
activ
phosphatidylinositol
iiib
comparison
aforement
hostfactor
direct
compound
also
azaspiro
dihydrotriazin
may
repres
valid
hit
worthi
assess
develop
effici
antivir
agent
inhibit
hdhfr
enzym
order
verifi
host
factor
dhfr
inhibit
mechan
action
novel
azaspiro
dihydrotriazin
exploit
antivir
effect
potent
compound
assay
recombin
hdhfr
enzym
display
submicromolar
low
micromolar
ki
valu
tabl
interestingli
compound
exhibit
inhibitori
behaviour
ki
hdhfr
compar
antivir
activ
ec
show
influenza
b
viru
fact
potent
compound
ec
mm
provid
lowest
ki
valu
equal
mm
less
effect
compound
ec
mm
possess
highest
inhibit
constant
ki
mm
therefor
previous
demonstr
cycloguanillik
dihydrotriazin
host
human
dhfr
found
molecular
target
novel
azaspiro
dihydrotriazin
deriv
previou
work
toward
identif
novel
safe
antivir
agent
explor
molecular
dock
pose
cycloguanillik
dihydrotriazin
deriv
featur
promis
antiinfluenza
activ
xray
crystallograph
structur
human
dhfr
chosen
xray
data
includ
host
enzym
complex
pyridopyrimidinebas
inhibitor
pdb
code
resolut
fig
virtu
relat
structur
similar
dihydrotriazin
scaffold
cocrystal
ligand
previou
dock
calcul
allow
gain
better
understand
mechan
action
first
seri
deriv
shown
fig
cocrystal
inhibitor
display
two
hbond
two
amin
group
link
pyrimidin
core
carbonyl
group
sidechain
respect
notabl
kind
contact
thought
relev
dhfr
inhibitor
activ
addit
bicycl
aromat
ring
involv
stack
interact
ring
establish
van
der
waal
contact
base
previou
find
introduct
bulki
group
cycloalkyl
ring
c
substitut
dihydrotriazin
core
caus
differ
posit
deriv
respect
refer
compound
fact
kind
substitu
forc
central
ring
establish
hbond
one
nh
group
convers
smaller
substitu
better
toler
especi
combin
meta
substitut
phenyl
ring
n
dihydrotriazin
ring
accordingli
promis
cycloguanillik
dihydrotriazin
deriv
hdhfr
k
mm
share
common
dock
mode
featur
two
hbond
thank
two
nh
group
onto
dihydrotriazin
scaffold
fig
dock
pose
compound
depict
particular
dimethyl
substitut
dihydrotriazin
core
togeth
lipophil
substitu
meta
posit
phenyl
ring
shown
featur
phenyl
moieti
fig
detail
xray
crystallograph
complex
hdhfr
inhibitor
c
atom
green
import
residu
label
colour
atom
type
interpret
refer
colour
figur
legend
reader
refer
web
version
articl
prove
particularli
effect
herein
explor
dock
studi
effect
replac
dimethyl
substitut
c
dihydrotriazin
fold
azaspirocontain
substitu
along
introduct
differ
substitut
phenyland
benzylr
alkyl
chain
link
posit
main
core
deriv
see
fig
kind
decor
design
aim
clarifi
relev
steric
properti
dihydrotriazin
target
hdhfr
fact
azaspiro
deriv
could
allow
better
fulfil
requir
set
forth
pyridopyrimidin
scaffold
anilin
ring
refer
compound
inde
dock
result
suggest
benefici
role
play
azaspiro
group
bear
aromat
substitu
sinc
aptli
superpos
anilin
moieti
refer
compound
display
compar
pattern
hydrophob
contact
surround
residu
predict
stabil
inhibitor
enzym
caviti
tabl
concomit
presenc
meta
substitut
phenyl
ring
tether
azaspiro
dihydrotriazin
core
impair
activ
deriv
respect
cycloguanillik
dihydrotriazin
deriv
lack
azaspiro
moieti
especi
decor
electrondonor
group
contrari
presenc
lipophil
electronwithdraw
group
eg
chlorin
meta
posit
phenyl
ring
sometim
allow
inhibitor
maintain
one
two
key
hbond
enzym
involv
see
fig
interestingli
potent
compound
featur
valuabl
antiinfluenza
b
activ
mean
ec
mm
display
addit
stack
interact
project
aforement
phenyl
ring
toward
also
one
hbond
carbonyl
oxygen
atom
sidechain
base
data
combin
carbonyl
hbond
acceptor
moieti
aromat
lipophil
group
benzoyl
moieti
would
prefer
accordingli
predict
energi
valu
complex
list
tabl
lower
congen
featur
aliphat
group
piperidin
nitrogen
see
seem
support
lack
activ
deriv
unsubstitut
posit
bear
variabl
phenyl
ring
n
dihydrotriazin
see
ec
mm
deriv
character
alkyl
chain
n
dihydrotriazin
fig
consid
compound
influenza
b
viru
ec
mm
exhibit
effect
dock
mode
within
enzym
caviti
shown
fig
flexibl
alkyl
side
chain
permit
dihydrotriazin
portion
ligand
fill
bind
crevic
better
refer
compound
previou
congen
decor
conform
rigid
aromat
ring
n
dihydrotriazin
notabl
allow
detect
one
hbond
sulfon
moieti
display
hbond
interestingli
presenc
oxygen
atom
along
aliphat
chain
place
n
allow
intramolecular
hydrogen
contact
surround
nh
group
onto
dihydrotriazin
core
consequ
overal
posit
ligand
orient
second
nh
group
toward
azaspiro
portion
sulfon
group
properli
recapitul
bind
mode
anilin
fragment
refer
compound
work
repres
followup
previou
investig
dihydrotriazinebas
deriv
dual
antivir
agent
influenza
rsv
virus
act
host
factor
dhfr
new
compound
seri
nitrogen
spiropiperidin
nucleu
allow
studi
role
differ
function
side
chain
understand
chemic
space
enhanc
interact
within
hdhfr
enzym
wherea
previou
seri
cycloguanillik
dihydrotriazin
emerg
highli
potent
influenza
b
rsv
inhibitor
display
nanomolar
activ
novel
azaspiro
dihydrotriazin
present
herein
possess
lower
antivir
activ
enzym
inhibit
assay
dhfrmediat
mechan
action
also
confirm
new
compound
previous
demonstr
cycloguanillik
dihydrotriazin
two
novel
compound
superior
activ
select
influenza
b
rsv
character
piperidin
nitrogen
bear
hbond
acceptor
moieti
link
aromat
lipophil
group
ptolylcarbonyl
carbamoyl
one
join
azaspiro
dihydrotriazin
also
compound
found
promis
new
hit
combin
methoxyethyl
chain
n
ethylsulfon
group
spiropiperidin
nitrogen
thu
besid
previous
studi
cycloguanillik
dihydrotriazin
deriv
also
adequ
substitut
azaspiro
dihydrotriazin
may
repres
valuabl
start
point
deserv
structur
optim
new
sar
insight
gather
studi
provid
crucial
inform
develop
class
host
dhfrdirect
antivir
agent
yield
proper
acyl
chlorid
mmol
ad
rt
stir
solut
deprotect
tetraazaspiro
compound
mmol
ml
dri
thf
ml
et
n
mmol
reaction
maintain
rt
stir
h
test
refer
compound
prepar
mm
stock
solut
dmso
incub
cell
highest
test
concentr
mm
mm
ribavirin
full
panel
refer
compound
zanamivir
amantadin
rimantadin
ribavirin
dextran
acyclovir
brivudin
cidofovir
zidovudin
nevirapin
antivir
activ
determin
broad
panel
virus
use
cytopath
effect
cpe
reduct
formazanbas
cell
viabil
assay
unless
mention
otherwis
cell
line
viru
strain
atcc
human
influenza
r
fouchier
rotterdam
netherland
examin
madindarbi
canin
kidney
mdck
cell
kind
gift
matrosovich
marburg
germani
respiratori
syncyti
viru
rsv
strain
long
evalu
human
cervix
carcinoma
hela
cell
cell
also
use
vesicular
stomat
viru
vsv
coxsacki
viru
african
green
monkey
vero
cell
use
viru
sindbi
viru
coxsacki
viru
punta
toro
viru
yellow
fever
viru
stamaril
strain
follow
virus
investig
human
embryon
lung
fibroblast
hel
cell
herp
simplex
viru
type
vaccinia
viru
human
adenoviru
type
clinic
isol
vsv
human
coronaviru
e
final
activ
human
immunodefici
viru
type
assess
human
lymphoblast
cell
cell
line
subcultiv
medium
fetal
calf
serum
fc
influenza
assay
mdck
cell
kept
fcsfree
medium
ie
ultra
mdck
medium
lonza
contain
mgml
tpck
tosylphenylalanylchloromethylketon
treat
trypsin
cleav
influenza
hemagglutinin
achiev
multicycl
viru
replic
hela
vero
hel
cell
kept
medium
fc
cell
left
medium
fc
detail
regard
antivir
procedur
found
elsewher
cell
seed
plate
hela
vero
mdck
hel
cell
per
well
hela
vero
mdck
infect
one
day
later
reach
semiconflu
hel
infect
reach
confluenc
ie
day
seed
cell
cultur
infect
viru
multipl
infect
ccid
cell
cultur
infect
dose
ie
viru
dose
produc
infect
inocul
well
calcul
method
reed
muench
simultan
viru
serial
fivefold
dilut
test
refer
compound
ad
assess
compound
cytotox
mockinfect
plate
prepar
parallel
ad
medium
instead
viru
plate
incub
c
c
case
influenza
coronaviru
day
day
case
adenoviru
time
manifest
cpe
visibl
untreat
viru
control
monolay
show
depend
viru
cell
round
shrink
lysi
cellcel
fusion
microscopi
perform
score
cpe
ie
score
correspond
cell
show
cpe
microscopi
also
done
monitor
cytotox
express
minimum
cytotox
concentr
ie
test
compound
concentr
caus
minim
chang
cell
morpholog
round
shrink
lysi
case
influenza
cpe
assay
complement
formazanbas
mt
cell
viabil
assay
celltit
aq
ueou
one
solut
cell
prolifer
assay
promega
hiv
similar
mtt
method
use
valu
ec
antivir
effect
concentr
calcul
interpol
use
semilog
dose
respons
curv
cpe
score
compoundtr
cell
convert
cpe
valu
rel
untreat
viru
control
set
mt
influenza
mtt
hiv
method
protect
viru
achiev
compound
defin
od
cpd
viru
od
contr
viru
od
contr
mock
od
contr
viru
x
od
cpd
viru
od
given
concentr
compound
virusinfect
cell
od
contr
viru
od
untreat
viru
control
od
contr
mock
od
untreat
mockinfect
control
also
valu
cc
cytotox
concentr
calcul
interpol
use
semilog
dose
respons
curv
cytotox
defin
od
cpd
mock
od
contr
mock
x
od
cpd
mock
od
given
concentr
compound
mockinfect
well
capabl
synthes
chemic
librari
inhibit
hdhfr
enzym
evalu
spectrophotometr
assay
multipl
reader
multiskango
e
thermofish
monitor
enzymat
degrad
dhf
substrat
dihydrofol
nm
inhibitor
compound
firstli
dissolv
dmso
vv
order
initi
concentr
equal
mm
assay
steadyst
condi
dhf
nadph
measur
see
fig
inhibit
assay
perform
consid
final
volum
equal
ml
detail
sever
reagent
ad
follow
order
te
buffer
hdhfr
enzym
concentr
mm
inhibitor
compound
singl
evalu
concentr
dhf
substrat
concentr
mm
ultrapur
water
volum
ml
end
nadph
ad
reaction
mixtur
concentr
valu
equal
mm
start
catalyt
reaction
inhibit
effect
observ
dmso
enzym
activ
rate
rang
vv
compound
built
parameter
gasteigerhuckel
method
energi
minim
within
moe
use
forcefield
ligand
use
proton
state
dock
calcul
within
xray
structur
human
dhfr
pdb
code
perform
use
leadit
softwar
suit
wwwbiosolveitcom
includ
flexx
score
algorithm
base
calcul
bind
free
energi
mean
gibbshelmholtz
equat
softwar
detect
bind
site
defin
radiu
far
cocrystal
ligand
order
set
spheric
search
space
dock
approach
standard
set
dock
strategi
follow
choos
socal
hybrid
approach
enthalpi
entropi
criteria
relat
score
function
evalu
describ
literatur
deriv
dock
pose
priorit
score
valu
lowest
energi
pose
compound
dock
protein
structur
ligand
refin
rescor
assess
algorithm
hyde
includ
leadit
softwar
hyde
modul
consid
dehydr
enthalpi
hydrogen
bond
final
reliabl
select
dock
pose
assess
use
ps
run
molecular
dynam
md
constant
temperatur
follow
allatom
energi
minim
lowmodemd
implement
moe
softwar
kind
modul
allow
perform
exhaust
conform
analysi
ligandreceptor
bind
site
complex
previous
discuss
case
studi
mt
fg
conceiv
studi
design
compound
vf
lg
synthes
compound
provid
structur
character
ln
perform
cellbas
assay
ms
mpc
perform
enzymat
assay
ec
perform
comput
research
mt
ln
mpc
analyz
discuss
result
mt
ln
ec
fg
wrote
paper
